Genetic Technologies Limited (GNTLF) 20-F2010 FY Annual report (foreign)

Filed: 21 Dec 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: AASB, ac, acc, aggravated, Agouron, ally, amorti, Ancestry, arena, arty, augment, bargain, Beckman, beginni, Biopharmaceutical, Boulevard, BRC, Brea, breeder, BREVAGen, BREVAGenTM, Bristol, Britain, BScAgr, CA, cap, Cape, Carolina, ce, Centocor, channel, Charlotte, clinician, club, confined, constructiv, Coulter, credibility, creditor, criter, Crude, culture, CVT, degenerative, Delaware, deoxyribonucleic, depr, der, dive, DuPont, Dutton, eciation, ed, endocrinology, envisage, eptable, eq, er, EraGen, es, espeople, evidenced, extinguished, Extinguishing, follo, fundraising, Gail, GBP, genix, ggregate, Gilead, Gippsland, Greece, HC, healt, heard, hether, Highway, honor, IASC, icer, ICPBio, ict, IFRIC, ill, impede, incremental, infrequent, installment, instalment, interestingly, Interleukin, Iowa, IVD, Jasenko, JEB, Johnston, judgme, Junglinster, Kennel, lag, leadership, Leveque, lic, licen, lifetime, lity, Lort, lty, Luxembourg, Madison, mainland, mance, Maryville, membership, Mountain, MP, nematode, Newton, ng, nnual, noti, notification, ns, nts, nvestment, Oakeshott, Oceania, omoting, online, ontinued, oth, pa, Parkway, Parliament, pena, perfor, Phenogen, Pioneer, Pleasingly, Plough, pr, prioritized, proactive, producti, profitabi, prognostic, propert, pub, quo, Ranexa, realign, Recital, Regulatio, remainin, resemblance, restr, Rob, robotic, Rockhampton, Rosetta, rsification, ry, sal, salespeople, se, skewed, Solvay, sort, Southbank, Squibb, staffing, Sterling, stipulated, striking, Stuart, subsidized, surveillance, techn, ted, Tennessee, theoretically, timeline, tion, Treasu, Trimgen, turnaround, uipment, unauthorized, unconfirmed, underway, Uni, unrelated, Upjohn, ure, USPTO, versed, virtue, voti, VP, welfare, Westpac, whethe, wi, wing, Wisconsin, won, zation

Removed: ACA, addictive, ago, annualized, antiparasitic, ATO, AXA, Barclay, book, BSc, Catherine, clarified, Cobon, consistently, cooperated, Diagnostik, exited, expiration, explanation, expressing, GAAP, graphically, Henry, herd, hiring, histocompatability, HR, influential, Ingelheim, Institut, irrevocable, Luisa, Mayne, mechanism, Medizinische, monopoly, multigene, nullification, organizational, outline, PGDipHRM, promoting, proved, pursued, recognising, renewal, restated, scoring, selection, static, strongly, suspected, tabular, Tasmania, undisclosed, unsuccessful, voluntary, web, workload, wrongdoing

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

GNTLF similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 13.02

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE U.S. SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Genetic Technologies Limited (the “Company”) on Form 20-F for the fiscal year ended June 30, 2010, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas Godfrey Howitt, Chief Financial Officer, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the U.S. Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the U.S. Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Thomas G. Howitt
Name:	Thomas G. Howitt
	Chief Financial Officer

December 17th, 2010